VT3989

DRUG2 trials

Sponsors

Vivace Therapeutics, Inc

Conditions

MesotheliomaNSCLCPleural MesotheliomaSolid Tumor, Adult

Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

RecruitingNCT04665206

Vivace Therapeutics, IncMesothelioma, NSCLC, Solid Tumor, Adult

Start: 2021-03-24End: 2030-03-02Target: 434Updated: 2026-04-02

Phase 3

A Phase 3 Trial in Advanced Epithelioid Mesothelioma

Not yet recruitingNCT07824986

Vivace Therapeutics, IncMesothelioma, Pleural Mesothelioma

Start: 2026-12-01End: 2031-01-01Target: 350Updated: 2026-09-17

Related Papers

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.

2025-10-197 citations

Abstract 4728: The selective Yap/Tead inhibitor TY-1054 re-sensitizes acquired resistance to multiple tyrosine kinase-based targeted therapies

Cancer Research2025-04-21

Abstract LB033: Identification of small molecule Pan-TEAD inhibitors disrupting YAP-TEAD protein-protein interaction and targeting gastric cancer cells

Cancer Research2024-04-051 citations

Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <i>in vitro</i> and <i>in vivo</i>

Cancer Research2023-04-043 citations